Details of the Drug

General Information of Drug (ID: DMOQ81Y)

Drug Name
Vernakalant
Synonyms
Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Phase 3 [1]
Affected Organisms
Humans and other mammals
ATC Code
C01BG11: Vernakalant
C01BG: Other antiarrhythmics, class I and III
C01B: ANTIARRHYTHMICS, CLASS I AND III
C01: CARDIAC THERAPY
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 349.5
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 3.9 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 10 min [2]
Clearance
The total body clearance of drug is 0.41 L/h/kg []
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [3]
Metabolism
The drug is metabolized via the CYP2D6 mediated O-demethylation []
Vd
The volume of distribution (Vd) of drug is approximately 2 L/kg []
Chemical Identifiers
Formula
C20H31NO4
IUPAC Name
(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
Canonical SMILES
COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
InChI
InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
InChIKey
VBHQKCBVWWUUKN-KZNAEPCWSA-N
Cross-matching ID
PubChem CID
9930049
ChEBI ID
CHEMBL135956
CAS Number
794466-70-9
UNII
9G468C8B13
DrugBank ID
DB06217
TTD ID
D00OTL
INTEDE ID
DR1682
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.
2 European Medicines Agency Summary of product characteristics
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.